Discovery - University of Dundee - Online Publications

Library & Learning Centre

Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis

Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis

Research output: Contribution to journalArticle

View graph of relations


  • M. Adnan Nadir
  • Li Wei
  • Douglas H. J. Elder
  • Renata Libianto
  • Tiong K. Lim
  • Maheshwar Pauriah
  • Stuart D. Pringle
  • Alex D. Doney
  • Anna-Maria Choy
  • Allan D. Struthers
  • Chim C. Lang (Lead / Corresponding author)

Research units


Original languageEnglish
Pages (from-to)570-576
Number of pages7
JournalJournal of the American College of Cardiology
Issue number6
StatePublished - 2 Aug 2011


Objectives The purpose of this study was to investigate the impact of renin-angiotensin system blockade therapy on outcomes in aortic stenosis (AS).

Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are perceived to be relatively contraindicated in AS. However, inhibitors of the renin-angiotensin system may be beneficial in AS through their cardioprotective and beneficial effects on left ventricular remodeling.

Methods The Health Informatics dispensed prescribing, morbidity, and mortality database for the population of Tayside, Scotland, was linked through a unique patient identifier to the Tayside echocardiography database (> 110,000 scans). Patients with a diagnosis of AS from 1993 to 2008 were identified. Cox regression model (adjusted for confounding variables) and propensity score analysis were used to assess the impact of ACEIs or ARBs on all-cause mortality and cardiovascular (CV) events (CV death or hospitalizations).

Results A total of 2,117 patients with AS (mean age 73 +/- 12 years, 46% men) were identified and 699 (33%) were on ACEI or ARB therapy. Over a mean follow-up of 4.2 years, there were 1,087 (51%) all-cause deaths and 1,018 (48%) CV events. Those treated with ACEIs or ARBs had a significantly lower all-cause mortality with an adjusted hazard ratio of 0.76 (95% confidence interval: 0.62 to 0.92, p < 0.0001) and fewer CV events with an adjusted hazard ratio of 0.77 (95% confidence interval: 0.65 to 0.92, p < 0.0001). The outcome benefits of ACEIs/ARBs were further supported by propensity score analysis.

Conclusions This large observational study suggests that ACEI/ARB therapy is associated with an improved survival and a lower risk of CV events in patients with AS. (J Am Coll Cardiol 2011;58:570-6) (C) 2011 by the American College of Cardiology Foundation



Library & Learning Centre

Contact | Accessibility | Policy